Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Pluvicto FDA Approved for Men with PSMA-Positive Metastatic Prostate Cancer

April 2022 Vol 8 No 2

On March 23, 2022, the FDA approved a novel therapy, Pluvicto (lutetium Lu 177 vipivotide tetraxetan; from Novartis/Advanced Accelerator Applications), for the treatment of adult men with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer after receiving an androgen receptor inhibitor and taxane-based chemotherapy.

Pluvicto is the first FDA-approved targeted radioligand therapy for patients with metastatic prostate cancer that combines a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle).

Oliver Sartor, MD

“The approval of Pluvicto is an important clinical advancement for people with progressing [metastatic prostate cancer], as it can significantly improve survival rates for those who have limited treatment options,” said Oliver Sartor, MD, Medical Director at Tulane Cancer Center in Louisiana. “Pluvicto is a step forward in the evolution of precision medicine for prostate cancer.”

On the same day, the FDA approved Locametz (gallium Ga 68 gozetotide), a radioactive diagnostic agent used for PET scanning of PSMA-positive lesions and for selecting patients with metastatic prostate cancer who should receive Pluvicto. This is the first radioactive diagnostic agent approved by the FDA for selecting patients for a radioligand therapeutic agent.

The approval of Pluvicto was based on results of the VISION study, a randomized, multicenter, open-label clinical trial of 831 patients with progressive, PSMA-positive metastatic prostate cancer. The patients were divided into 2 groups: 551 patients received Pluvicto plus best standard of care, and 280 patients received best standard of care alone. The patients received Pluvicto every 6 weeks for up to 6 doses plus best standard of care or best standard of care alone.

The overall survival was significantly better with Pluvicto plus best standard of care compared with best standard of care alone. The average overall survival was 15.3 months with Pluvicto plus best standard of care compared with 11.3 months with best standard of care alone.

The most common side effects with Pluvicto were fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation. The most common laboratory abnormalities that worsened in patients who received Pluvicto were decreased levels of lymphocytes, hemoglobin, leukocytes, platelets, calcium, and sodium.

Treatment with Pluvicto may be associated with several risks, including risk of exposure to radiation, myelosuppression, and kidney side effects.

Recommended For You